Researchers Discover New Antibiotic for Drug-resistant Bacteria with AI
McMaster University and the Massachusetts Institute of Technology researchers using artificial intelligence (AI) have discovered a new type of antibiotic
Read more
DISEASES
Ironwood to Acquire VectivBio for $1B in Late-stage Digestive Therapy Deal
The $1 billion acquisition deal is set to advance Ironwood’s vision of becoming the leading gastrointestinal healthcare company. Ironwood Pharmaceuticals,
Read more
FDA Approves Krystal Biotech’s VYJUVEK™: First Redosable Skin-disorder Gene Therapy
Krystal Biotech, Inc., a Pennsylvania-headquartered biotech company specialising in genetic medicines for rare diseases, announced on Friday that the US
Read more
Coya Therapeutics’ COYA 301 (interleukin-2) Shows Promising Results in Open Label Alzheimer’s Study
Coya Therapeutics’ investigational low-dose interleukin-2 (IL-2) for subcutaneous administration, COYA 301, has been found to increase Treg function and halt
Read more
Eisai Partners with BlissBio to Jointly Develop ADC for Multiple Cancer Types
Eisai Co., Ltd. revealed that it has partnered with Bliss Biopharmaceutical (Hangzhou) Co., Ltd. to develop BB-1701, an antibody-drug conjugate
Read more
UK Study Finds Autoimmune Disorders Affect Around One in Ten People
According to a recent UK population-based study published in The Lancet, approximately one in ten individuals are now affected by
Read more
Chiesi and Protalix’s Therapy for Fabry Disease Receives Marketing Approval from EC
Chiesi Global Rare Diseases and Protalix BioTherapeutics, Inc. have received marketing authorization from the European Commission (EC) for their drug,
Read more
Janssen Claims First Global Approval for AKEEGA®
Janssen has received its first worldwide approval for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) as EC Authorized treatment
Read more
GSK to Acquire BELLUS Health for $2 Billion
GSK has entered into an agreement to acquire BELLUS Health, a Canadian late-stage biopharmaceutical company, for a total consideration of
Read more
FDA Grants Fast Track Designation for Shionogi’s Investigational COVID-19 Oral Antiviral
Japanese multinational pharmaceutical company Shionogi & Co., Ltd,. announced at the beginning of April that the U.S. FDA has granted
Read more